Evidence map›Paper›PMID 32628816›Full record

ArticleJournal of the International AIDS Society2020

Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study.

Tavitiya Sudjaritruk, Sirinya Teeraananchai, Azar Kariminia, Keswadee Lapphra, Nagalingeswaran Kumarasamy, Moy S Fong, Rawiwan Hansudewechakul, Torsak Bunupuradah, Penh Sun Ly, Revathy A Nallusamy and 3 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Journal of the International AIDS Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 5 countries.

Tavitiya SudjaritrukDepartment of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID 0000-0002-3686-4623
Sirinya TeeraananchaiThe HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Azar KariminiaThe Kirby Institute, UNSW Australia, Sydney, Australia.
Keswadee LapphraDepartment of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.ORCID 0000-0002-4513-5924
Nagalingeswaran KumarasamyChennai Antiviral Research and Treatment Clinical Research Site, VHS-Infectious Diseases Medical Centre, VHS, Chennai, India.
Moy S FongHospital Likas, Kota Kinabalu, Malaysia.
Rawiwan HansudewechakulChiangrai Prachanukroh Hospital, Chiang Rai, Thailand.
Torsak BunupuradahThe HIV Netherlands Australia Thailand Research Collaboration, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Penh Sun LyNational Centre for HIV/AIDS, Dermatology and STDs, Phnom Penh, Cambodia.
Revathy A NallusamyPenang Hospital, Penang, Malaysia.
Annette H SohnTREAT Asia/amfAR - The Foundation for AIDS Research, Bangkok, Thailand.ORCID 0000-0002-0209-3285
Virat SirisanthanaResearch Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
TREAT Asia Pediatric HIV Observational Database of IeDEA Asia-Pacific
Chiang Mai University · THAustralian Wool Innovation (Australia) · AUChiangRai Prachanukroh Hospital · THHIV Netherlands Australia Thailand Research Collaboration · THKasetsart University · THNational Center for HIV/AIDS, Dermatology and STD · KHPenang Adventist Hospital · MYSiriraj Hospital · THVoluntary Health Services Hospital · IN

Funding

The Asia-Pacific HIV Research CollaborationU01AI069907 · NIAID · FOUNDATION FOR AIDS RESEARCH · PI ANNETTE H SOHN · 2006 to 2026
$44.8M
FIC NIH HHSNCI NIH HHSNHLBI NIH HHSNIAAA NIH HHSNIAID NIH HHS U01 AI069907NICHD NIH HHSNIDA NIH HHSNIDDK NIH HHSNIH HHS U01AI069907NIMH NIH HHS
6 · The paper itself

Abstract

introductionThe clinical relevance of low-level viraemia (LLV) and virological outcomes among children living with HIV (CLHIV) remains controversial. This study aimed to determine the impact of LLV on virological failure (VF) among Asian CLHIV on first-line combination antiretroviral therapy (cART).

methodsCLHIV aged <18 years, who were on first-line cART for ≥12 months, and had virological suppression (two consecutive plasma viral load [pVL] <50 copies/mL) were included. Those who started treatment with mono/dual antiretroviral therapy, had a history of treatment interruption >14 days, or received treatment and care at sites with a pVL lower limit of detection >50 copies/mL were excluded. LLV was defined as a pVL 50 to 1000 copies/mL, and VF as a single pVL >1000 copies/mL. Baseline was the time of the second pVL < 50 copies/mL. Cox proportional hazards models were performed to assess the association between LLV and VF.

resultsFrom January 2008 to September 2016, 508 CLHIV (55% female) were eligible for the study. At baseline, the median age was 9.6 (IQR: 7.0 to 12.3) years, cART duration was 1.4 (IQR: 1.3 to 1.8) years, 97% of CLHIV were on non-nucleoside reverse transcriptase inhibitor-based regimens, and the median CD4 was 25% (IQR: 20% to 30%). Over a median follow-up time of 6.0 (IQR: 3.1 to 8.9) years from baseline, 86 CLHIV (17%) had ever experienced LLV, of whom 32 (37%) had multiple LLV episodes. Female sex, living in Malaysia (compared to Cambodia), having family members other than biological parents/grandparents as a primary caregiver, and baseline CD4 < 25% increased risk of LLV. Overall, 115 children (23%) developed VF, corresponding to a rate of 4.0 (95%CI: 3.4 to 4.9) per 100 person-years of follow-up (PYFU). VF was greater among children who had ever experienced LLV compared with those who maintained virological suppression throughout the study period (8.9 vs. 3.3 per 100 PYFU; p < 0.001). In multivariable analyses, ever experiencing LLV was associated with increased risk of subsequent VF (adjusted hazard ratio: 3.01; 95%CI: 1.97 to 4.60).

conclusionsLLV increased the risk of subsequent VF among Asian CLHIV who had previously been suppressed on first-line cART. Adherence interventions and additional targeted pVL monitoring may be warranted among children with LLV to facilitate early detection of VF.

Indexed as

Viral LoadAdolescentAnti-HIV AgentsCambodiaChildCohort StudiesDrug Therapy, CombinationFemaleHIV-1HIV InfectionsHumansMalaysiaMaleProportional Hazards ModelsRetrospective StudiesReverse Transcriptase InhibitorsAnti-HIV AgentsReverse Transcriptase InhibitorsAsiapaediatrictreatment failureviraemiaviral blipviral rebound

Identifiers

PMID32628816
PMCPMC7338042
OpenAlexW3041099306

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.